| Literature DB >> 18000990 |
Mirjam B Zeisel1, George Koutsoudakis, Eva K Schnober, Anita Haberstroh, Hubert E Blum, François-Loïc Cosset, Takaji Wakita, Daniel Jaeck, Michel Doffoel, Cathy Royer, Eric Soulier, Evelyne Schvoerer, Catherine Schuster, Françoise Stoll-Keller, Ralf Bartenschlager, Thomas Pietschmann, Heidi Barth, Thomas F Baumert.
Abstract
UNLABELLED: Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide. Scavenger receptor class B type I (SR-BI) has been shown to bind HCV envelope glycoprotein E2, participate in entry of HCV pseudotype particles, and modulate HCV infection. However, the functional role of SR-BI for productive HCV infection remains unclear. In this study, we investigated the role of SR-BI as an entry factor for infection of human hepatoma cells using cell culture-derived HCV (HCVcc). Anti-SR-BI antibodies directed against epitopes of the human SR-BI extracellular loop specifically inhibited HCVcc infection in a dose-dependent manner. Down-regulation of SR-BI expression by SR-BI-specific short interfering RNAs (siRNAs) markedly reduced the susceptibility of human hepatoma cells to HCVcc infection. Kinetic studies demonstrated that SR-BI acts predominately after binding of HCV at an entry step occurring at a similar time point as CD81-HCV interaction. Although the addition of high-density lipoprotein (HDL) enhanced the efficiency of HCVcc infection, anti-SR-BI antibodies and SR-BI-specific siRNA efficiently inhibited HCV infection independent of lipoprotein.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18000990 DOI: 10.1002/hep.21994
Source DB: PubMed Journal: Hepatology ISSN: 0270-9139 Impact factor: 17.425